AZN vs BLCO

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 2/9, indicating weak operational and balance sheet performance. Despite a reasonable Price/Book of 0.94 and a Debt/Equity ratio of 0.76, the company is unprofitable with a negative ROE of -4.50% and a profit margin of -6.13%. Earnings have collapsed year-over-year (-147.1%) and the last four quarters missed estimates by an average of -154.31%, signaling deteriorating fundamentals. While revenue growth of 7.10% and a gross margin above 59% provide some operational strength, the persistent earnings deterioration and lack of profitability undermine valuation support.